Genetic Engineering Publications - GEG Tech top picks

CAR T cell therapies directed against CD19 have demonstrated high rates of pre-malignant responses in patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL). However, long-term data on these therapies are limited. However, according to the results of a long-term follow-up analysis of a phase 1 study NCT01593696 published in the Journal of Clinical Oncology, sequential CAR-T cell therapy directed against CD19.28ζ followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) induces durable disease control in a significant population of pediatric and young adult patients with B-cell ALL. In the Phase 1 clinical trial, two doses of CAR T cell-based therapies were used, either an infusion of 1 x 10^6 CAR T cells/ kg administered on day 0, or an infusion of 3 x 10^6 CAR T cells/ kg administered on day 0. The maximum tolerated dose was defined as 1 x 10^6 CAR T cells / kg. Overall, 53 patients were enrolled in the study; 51 patients had B-ALL and 2 had diffuse large B-cell lymphoma. Complete responses were observed in 62% (n=31) of patients infused with CD19.28ζ directed CAR T cells (n=50).